Skip to content

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Regulatory evidence

Primary-source signals organized for decisions.

Browse governed regulatory records and connect source evidence to technical context, XGene analysis, and practical pathways.

Regulatory evidenceDecision

01Source

02Agency

03Context

04Action

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Warning Letters

Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA 483 Trend Analysis — March-May 2026: What Inspectors Are Finding at Compounding Pharmacy and Outsourcing Facility Aseptic Programs Right Now XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zydus Pharmaceuticals Class II Recall — Mirabegron Extended-Release Tablets: The Manufacturing Quality Signal Behind the Notice and What It Reveals About Nitrosamine Control Strategy XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must Know XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Consent Decrees

Inside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

FDA Guidance / Regulatory Developments

FDA’s New Container Closure and Device Constituent Part Draft Guidance for Biosimilars — Why the Comparative Task Analysis Framework Deserves a Formal XGene-Style Comment XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

International Enforcement

International GMP Enforcement — Q3 2026: Pattern Analysis Across 14 Actions and What the Trend Signals for Global Pharmaceutical Quality XGene Regulatory Intelligence · Aug 22, 2026 Open Regulatory Record →

Public library

Browse the published XGene collection.

Insights Hub →

Regulatory Record Pharmathen International Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize On May 27, 2026, FDA issued Warning Letter 320-26-80 to Pharmathen International S.A., a sterile drug product manufacturer located in Sapes, Rodopi Prefecture, Greece (Facility Establishment Identifier —… Aug 22, 2026 →

Regulatory Record Jubilant HollisterStier Warning Letter: Aseptic Processing Failures and the CMC Pattern Every Sterile Products Quality Director Must Recognize On May 28, 2026, FDA's Center for Drug Evaluation and Research issued Warning Letter 320-26-81 to Jubilant HollisterStier General Partnership at its Kirkland, Quebec facility — and the… Aug 22, 2026 →

Regulatory Record Thomas Brunner Hygiene GmbH Warning Letter: Zero Release Testing and an OTC Monograph Trap Every Formulator Must Recognize Thomas Brunner Hygiene GmbH, a manufacturer of over-the-counter (OTC) antiperspirant products in Albershausen, Germany, received FDA Warning Letter 320-26-106 on July 24, 2026 — issued not after an… Aug 22, 2026 →

Regulatory Record Woodbine Products Company Inc. Warning Letter: Laboratory Controls Failure and the CMC Pattern Every OTC Manufacturer Must Recognize Woodbine Products Company Inc., a Medina, Ohio manufacturer of over-the-counter topical and ethanol-based drug products, received FDA Warning Letter 320-26-107 on July 27, 2026, following a February 9–13,… Aug 22, 2026 →

Regulatory Record Dabur India Limited Warning Letter: Data Integrity and the CMC Pattern Every Quality Unit Leader Must Recognize Dabur India Limited, the New Delhi-headquartered consumer health and pharmaceutical group, received FDA Warning Letter 320-26-105 on July 24, 2026, following a January 12–16, 2026 inspection of its… Aug 22, 2026 →

Regulatory Record CoValence Laboratories Warning Letter: Process Validation Failure and the CMC Pattern Every OTC Drug Quality Director Must Recognize On July 16, 2026, FDA issued Warning Letter 320-26-104 to Island Kinetics, Inc. d.b.a. CoValence Laboratories, Chandler, Arizona, following an inspection conducted January 14 to 23, 2026 at… Aug 22, 2026 →

Regulatory Record Spa De Soleil Warning Letter: Out-of-Specification Investigation Failure and the CMC Pattern Every OTC Drug Quality Director Must Recognize On July 8, 2026, FDA's Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-100 (MARCS-CMS 728508) to Spa De Soleil, Inc., an over-the-counter (OTC) topical drug… Aug 22, 2026 →

Regulatory Record BioMylz Warning Letter: Data Integrity Collapse and the CMC Pattern Every Quality Assurance Director Must Recognize On July 13, 2026, FDA issued Warning Letter 320-26-103 to BioMylz Pvt. Ltd., a contract drug manufacturer operating at Facility Establishment Identifier (FEI) 3013697420 in Bengaluru, Karnataka, India,… Aug 22, 2026 →

Regulatory Record Shimoga Chemicals Warning Letter: Data Integrity Failure and the CMC Pattern Every API Quality Director Must Recognize On July 13, 2026, FDA issued Warning Letter 320-26-101 (MARCS-CMS 727904) to Shimoga Chemicals, an active pharmaceutical ingredient (API) manufacturer at W57A, MIDC, Kupwad, Sangli, Maharashtra, India, following… Aug 22, 2026 →

Regulatory Record Almon Healthcare Warning Letter: Deliberate Raw Material Mislabeling and the CMC Pattern Every API Supply Chain Quality Director Must Recognize On July 13, 2026, FDA issued Warning Letter 320-26-102 to Almon Healthcare Private Limited, an active pharmaceutical ingredient manufacturer at Plot No 4, Sankalp Industrial Estate, Bavala, Ahmedabad,… Aug 22, 2026 →

Regulatory Record International Medication Systems Limited Warning Letter: Aseptic Contamination Control Failure and the CMC Pattern Every Sterile Injectable Quality Director Must Recognize On July 2, 2026, FDA issued Warning Letter 320-26-99 to International Medication Systems Limited, a South El Monte, California manufacturer of both active pharmaceutical ingredient (API) and aseptically… Aug 22, 2026 →

Regulatory Record Macau-Union Pharmaceutical Warning Letter: Process Validation and the CMC Pattern Every OTC Quality Director Must Recognize On May 29, 2026, FDA issued Warning Letter 320-26-83 to Macau-Union Pharmaceutical Limited, a drug manufacturing facility operating from Macao SAR China. The letter, issued by the Center… Aug 22, 2026 →

Previous 1 2 3 4 5 Next

XGene Intelligence Discovery

Search this collection and connected XGene intelligence.

Stay within this content family or broaden into related evidence, analysis, resources, and services.

Search Content Domain CMC Authority Action Modality Region Sort

Loading governed XGene intelligence…

Regulatory and quality consulting for pharmaceutical, biotechnology, and medical-device organizations.

Services

Regulatory Strategy CMC & Module 3 Quality & Data Integrity Inspection Readiness AI-Enabled CMC

Insights

Insights Hub Regulatory Intelligence Center Articles & Case Studies CMC Intelligence Resource Center Podcast Video

Company

About XGene Who We Help Contact Book a Call Discuss a Project

© 2026 XGene LLC · XGene Consulting Services · Troy, Michigan Privacy & Cookies · Terms · Disclaimer · Accessibility

XGene Navigator

Find the right evidence, insight, or service.

Search XGene

Services Regulatory Evidence Analysis FAQs Resources Video Podcast

Start typing to search across XGene's public knowledge base.

Saved for later

My XGene Library

Save public XGene articles, records, resources, and services on this device for quick return.

Saved items

Recently viewed